Module -1.

Q. Explain the patent co-operation treaty briefly and the applicable provisions of the
patented act 1970.

Ans :- Introduction

In the modern global economy, inventions are no longer limited to one country. Inventors often
seek protection in multiple nations to prevent unauthorized use of their innovation. However,
patent rights are territorial, meaning protection granted in one country does not automatically
apply elsewhere. Filing separate patent applications in each country can be expensive and time-
consuming.

To overcome this challenge, the Patent Cooperation Treaty (PCT) was established in 1970 under
the World Intellectual Property Organization (WIPO). It allows inventors to file a single
international patent application that can later be recognized in multiple member countries. India
became a member of the PCT in 1998, and the Patents Act, 1970, along with Patent Rules, 2003,
provides specific provisions for processing such international applications.

The PCT facilitates global patent protection, reduces filing costs, and provides a preliminary
assessment of novelty and patentability, while leaving final grant to national offices.

II. Definition, Origin, and History

Definition:

The Patent Cooperation Treaty is an international agreement that allows inventors to file a single
patent application for protection in multiple countries.

The application undergoes an international search and optional preliminary examination before
entering national phases in member states.

Origin and History:

Established in 1970 under the auspices of WIPO (World Intellectual Property Organization).

Designed to address the challenges of filing patents in multiple countries individually.

Prior to PCT, inventors had to submit separate applications in each jurisdiction, increasing costs
and complexity.

PCT harmonizes international filing, but does not create a global patent; patent rights remain
territorial.
India became a member in 1998, integrating PCT provisions into the Patents Act, 1970, allowing
Indian inventors to use the treaty for filing abroad and enabling foreign inventors to seek
protection in India.

Significance:

Ensures priority rights under the Paris Convention are respected.

Facilitates international innovation, technology transfer, and global commercialization.

Provides legal certainty and preliminary guidance to inventors before entering costly national
phases.

III. Main Body

A. Background and Need for PCT

Territorial Nature of Patents:

Patents protect inventions within the borders of a specific country.

Without international treaties, inventors had to file applications separately in each jurisdiction.

Problems before PCT:

High cost of filing in multiple countries.

Risk of losing novelty because inventions could be published before filing abroad.

Difficulty in monitoring different national rules.

Solution through PCT:

Provides a single filing accepted by all member countries.

Offers a preliminary international search to assess patentability.

Delays the national phase entry, giving inventors time to plan strategically.

B. Structure and Procedure under PCT

International Application:

Filed in one language at the receiving office.

Must contain description, claims, drawings, and abstract.

International Search Report (ISR):

Conducted by an International Searching Authority (ISA).

Identifies prior art, assesses novelty and inventive step.

Helps applicant decide whether to proceed in national phase.

International Preliminary Examination:

Optional step.

Provides preliminary opinion on patentability.

Allows inventor to amend claims to comply with requirements of national patent offices.

National Phase Entry:

Inventor must enter national or regional phase in countries where protection is desired.

Time limit: usually 30–31 months from priority date.

Each national office examines application under local laws.

C. Applicable Provisions under Indian Patents Act, 1970

Section 7(1A):

Provides for international applications designating India.

Section 39:

Requires prior permission before filing abroad if invention originated in India.

Sections 135–139:

Deal with international arrangements and convention applications.

Section 135: Defines convention country.

Section 136: Recognition of convention applications claiming priority abroad.

Section 137: Recognition of PCT applications in India.

Section 138–139: Powers of the government to make rules and remove difficulties.
Patent Rules 2003 – Rules 19–22:

Deal with entry into national phase.

Procedures, forms, fees, and time limits for PCT applications.

D. Advantages of PCT

Cost-effective: One filing instead of multiple applications.

Time-saving: Delays national phase entry for strategic planning.

Preliminary Examination: Helps decide patentability before national filings.

Harmonization: Recognizes priority rights and maintains uniform standards.

Global Recognition: Facilitates international technology transfer.

E. Limitations and Criticisms

PCT does not grant international patents; final rights are national.

National laws may restrict patentability (e.g., Section 3(d) in India for pharmaceuticals).

Cost of entering multiple countries in national phase can still be high.

Developing countries may face resource constraints in filing and prosecuting applications.

F. Comparative Analysis

USA:

Allows single application under PCT.

Strong protection for biotech, GMOs, and software with technical effect.

Europe (EPC):

Technical inventions only; excludes abstract ideas or natural phenomena.

PCT application enters European phase.

India:

PCT recognized; national phase subject to Indian patent law, including Sections 3(d), 7, 39, 135–
139.
Focuses on public interest, access to medicine, and national priorities.

G. Landmark Case Laws Related to PCT and International Filing

Novartis AG v. Union of India (2013)

Issue: Whether a modified pharmaceutical substance filed under international standards is

patentable in India.

Held: Inventions must comply with Indian patent law (Section 3(d)), regardless of PCT filing.

Enercon (India) Ltd. V. Aloys Wobben (2013)

Issue: Priority rights in multiple international filings.

Held: Priority rights under Paris Convention and PCT recognized; protects international
applicants.

F. Hoffmann-La Roche Ltd. V. Cipla Ltd. (2008)

Issue: Applicability of international patent filing for drugs.

Held: Patent must satisfy Indian standards; PCT does not override domestic law.

Bayer Corporation v. Union of India (2011)

Issue: Recognition of international patent application.

Held: Indian patent office recognizes international application national phase only if Indian law
criteria met.

H. Conclusion

The Patent Cooperation Treaty (PCT) is a landmark international mechanism that simplifies
patent protection across multiple countries. It reduces costs, provides a preliminary patentability
check, and facilitates strategic filing in member states. In India, Sections 7, 39, 135–139 of the
Patents Act, 1970 regulate international applications under PCT, balancing global harmonization
with national public interest. Case laws like Novartis v. Union of India highlight that Indian
patentability standards override international filings. Overall, PCT strengthens global innovation
while preserving the territorial nature of patents, ensuring both inventors’ rights and public
welfare are protected.

Q. Elaborately discuss the provisions of international treaties, conventions and Indian law
for protecting and promoting patentes. State the rights and obligations of patentee.
Q. Discuss various international conventions and treaties regarding patentes.

Ans :- Introduction

Patents play a crucial role in encouraging innovation by granting inventors exclusive rights over
their inventions. With globalization, inventions often cross national borders, making it essential
to have international treaties and conventions to harmonize patent protection globally.

Several international instruments, including the Paris Convention (1883), Patent Cooperation
Treaty (1970), Budapest Treaty (1977), and TRIPS Agreement (1995), provide frameworks to
protect and promote patents. These treaties ensure inventors get protection in member countries,
recognize priority rights, and simplify international patent filing procedures.

India, as a member of these treaties, has incorporated their provisions into the Patents Act, 1970,
amended in 2005 to comply with TRIPS. These legal frameworks help balance the rights of
inventors with public interest, especially in sectors like pharmaceuticals and biotechnology.

Understanding patentee rights and obligations under these treaties and Indian law is vital to
ensure both protection of inventions and adherence to legal standards. Courts in India have
consistently emphasized the territorial nature of patents while acknowledging the importance of
international obligations.

II. Definition, Meaning, and Origin

Definition:

A patent is an exclusive right granted by a government to an inventor for a new, inventive, and
industrially applicable invention, allowing them to exclude others from making, using, or selling
the invention for a limited period.

Origin of International Patent Conventions:

The need for international protection arose as inventors sought to secure rights in multiple
countries.

Paris Convention (1883): First major international agreement to provide national treatment and
priority rights.

Patent Cooperation Treaty (1970): Created under WIPO to simplify multi-country filings.

Budapest Treaty (1977): Standardized deposit of microorganisms for biotech patents.

TRIPS Agreement (1995): Harmonized IP standards under WTO, ensuring minimum protection
globally.

History:
India joined the Paris Convention and PCT in 1998, ensuring international recognition of patents.

The Patents Act, 1970 was amended in 2005 to align with TRIPS, allowing product patents in
drugs and chemicals.

These international treaties provide procedural simplification, protection of priority rights, and
harmonized standards while national laws maintain sovereignty over patentability.

III. Main Body

A. International Conventions and Treaties

1. Paris Convention (1883)

Objective: Protect industrial property internationally.

Key Provisions:

National Treatment: Foreign inventors receive same rights as nationals.

Right of Priority: Filing in one member country allows 12 months priority in others.

Independence of Patents: One country’s decision does not affect another.

Significance: Protects inventors, encourages cross-border innovation.

2. Patent Cooperation Treaty (1970)

Objective: Simplify international patent filing.

Key Features:

Single international application.

International Search Report (ISR): Highlights prior art.

International Preliminary Examination: Optional step for patentability.

National Phase Entry: Filing in desired countries later.

India: Sections 7, 39, 135–139 of Patents Act, 1970 govern PCT applications.

3. Budapest Treaty (1977)

Objective: Standardize patenting of microorganisms.

Provisions:

Deposit of microorganism in recognized depository satisfies patent filing in all member states.

Importance: Facilitates biotech patent protection internationally.

4. TRIPS Agreement (1995)

Objective: Harmonize IP standards globally.

Key Features:

20-year patent term.

Minimum standards: novelty, inventive step, industrial applicability.

Flexibilities for developing countries.

India: Complied via Patents (Amendment) Act, 2005.

5. WIPO (1967)

Objective: Develop global IP standards and provide training, arbitration, dispute resolution.

India: Member since 1975; actively participates in international IP governance.

B. Indian Patent Law (Patents Act, 1970)

Objective: Protect inventions, encourage innovation, and promote public interest.

Relevant Sections for International Treaties:

Section 7(1A): International applications designating India.

Section 39: Prior permission before foreign filing.

Sections 135–139: Recognition of international applications and convention filings.

Patent Rules, 2003 (Rules 19–22): Procedures for PCT national phase entry.

Patentable Subject Matter:

Products and processes in all fields of technology.

Excludes inventions contrary to law, morality, or public health.

Patent Term: 20 years from filing date.

Rights of Patentee:

Exclusive Rights: Make, use, sell, license the invention.

Legal Remedies: File infringement suits.

Assignment and Licensing: Transfer rights commercially.

Obligations of Patentee:

Disclose invention clearly and fully in the specification.

Pay maintenance fees regularly.

Avoid abuse of monopoly rights that may harm public interest.

C. Comparative Analysis with Other Countries

USA: Allows PCT filings; strong protection including biotech and software patents.

Europe (EPC): Technical solutions only; software and discoveries excluded.

Canada & Japan: Recognize PCT; harmonize with local laws.

India: Ensures compliance with TRIPS; Section 3(d) protects public health in pharmaceuticals.

D. Landmark Case Laws

Novartis AG v. Union of India (2013)

Issue: Patentability of modified drugs under Indian law vs international filings.

Held: Must comply with Indian law (Section 3(d)) even if filed internationally.

Enercon (India) Ltd. V. Aloys Wobben (2013)

Issue: Priority rights in multiple filings.

Held: Paris Convention and PCT priority recognized.

F. Hoffmann-La Roche Ltd. V. Cipla Ltd. (2008)

Issue: Applicability of international filing for drugs.

Held: Indian patent office applies domestic criteria; PCT does not override.

Bayer Corporation v. Union of India (2011)

Issue: phase recognition of PCT application.

Held: National patent laws govern recognition and grant.

E. Importance and Impact

Simplifies international patent filing.

Protects rights of inventors and promotes innovation.

Facilitates technology transfer and foreign investment.

Balances public interest with inventor rights.

F. Limitations

PCT does not grant international patents.

National laws may restrict patentability.

Costly to enter multiple national phases.

Developing countries face resource constraints in filing and prosecution.

IV. Conclusion

International treaties and conventions like the Paris Convention, PCT, Budapest Treaty, and
TRIPS, along with Indian patent law, provide a robust framework to protect and promote patents.
They simplify international filing, respect priority rights, and harmonize global standards while
maintaining the territorial nature of patents. Indian law integrates these treaties while
safeguarding public interest, as highlighted in landmark cases like Novartis v. Union of India.
Patentees enjoy exclusive rights, but also have duties to disclose inventions and avoid abuse.
Together, these laws encourage innovation, technological advancement, and global
competitiveness.

Q. Patentability and patentable subject matter.

Ans :- Introduction
Patents are legal instruments that grant inventors exclusive rights over their inventions for a
limited period. The fundamental principle of patent law is to encourage innovation while
balancing public interest. Not every invention qualifies for a patent; it must satisfy certain
criteria of patentability.

Patentability refers to the conditions under which an invention can be legally protected as a
patent. These criteria ensure that only novel, useful, and inventive inventions receive protection,
preventing abuse of monopoly rights.

Patentable subject matter, on the other hand, refers to the types of inventions that can be granted
patents under law. The Patents Act, 1970 (India), along with international treaties like the Paris
Convention, PCT, and TRIPS, defines what can be patented and what is excluded to protect
public interest, morality, and health.

Understanding patentability and patentable subject matter is crucial for inventors, lawyers, and
policymakers to navigate legal protection, commercialize inventions, and prevent infringement.
Indian law provides a framework that incorporates international standards while maintaining
flexibility to protect public welfare, as seen in pharmaceuticals, biotechnology, and software
patents.

II. Definition, Meaning, and Origin

Definition

Patentability:

Patentability is the set of conditions an invention must satisfy to qualify for patent protection.

It ensures that only new, inventive, and industrially applicable inventions are granted exclusive
rights.

Patentable Subject Matter:

The types of inventions eligible for patent protection under law.

Includes products, processes, machines, compositions of matter, and improvements thereof.

Origin and History

The concept of patentability originates from European and English patent law in the 15 th–17th
centuries, aimed at promoting innovation and invention.

Paris Convention (1883): Provided international recognition and priority rights for patentable
inventions.

Patent Cooperation Treaty (1970): Simplified international patent applications.

TRIPS Agreement (1995): Set minimum standards of patent protection globally, including
patentable subject matter.

India:

Patents Act, 1970 defines patentable inventions (Sections 2, 3, 5, 6).

2005 amendment aligned India with TRIPS, introducing product patents for pharmaceuticals and
chemicals.

Patentable subject matter excludes natural phenomena, discoveries, abstract ideas, and inventions
contrary to law or morality.

III. Main Body

A. Criteria of Patentability

An invention must satisfy four essential conditions to be patentable under Indian law:

Novelty (Newness)

The invention must not have been published or known anywhere in the world before the date of
filing.

Prior publication in any journal, patent specification, or public use destroys novelty.

Section 2(1)(j) and Section 13 of the Patents Act.

Inventive Step (Non-obviousness)

The invention must not be obvious to a person skilled in the art.

Must show a technical advancement over existing knowledge.

Section 2(1)(ja) defines inventive step.

Industrial Applicability (Utility)

Must be capable of being made or used in industry.

Excludes abstract concepts, ideas, and scientific theories.

Patentable Subject Matter

Covered under Section 3 and Section 4 of the Patents Act.

Must not fall under excluded categories, such as:

Section 3(d): Mere discovery of new form of known substance without enhanced efficacy.

Section 3(e–k): Scientific principles, mathematical formulas, plants, animals, traditional

knowledge, computer programs per se.

B. Types of Patentable Subject Matter in India

Products – e.g., chemical compounds, machines, pharmaceutical drugs.

Processes – method of manufacturing or transforming products.

Machines – devices or mechanical inventions with new features.

Improvements – improvement of existing machines or processes.

Compositions of Matter – combination of substances that has a new utility.

Exclusions (Non-Patentable):

Section 3 lists non-patentable inventions, e.g.:

Discovery of natural substances.

Methods of agriculture or horticulture.

Scientific theories and mathematical methods.

Software per se (unless technical effect achieved).

C. International Perspective

Paris Convention (1883)

Requires countries to grant patents for inventions regardless of nationality.

Patent Cooperation Treaty (1970)

Simplifies filing for inventions in multiple countries.

TRIPS Agreement (1995)

Requires member countries to provide patent protection for inventions in all fields of technology.

Allows exclusions for public order, morality, and health.

Comparative:

USA: Patentable subject matter includes software with technical effect, biotech inventions.

Europe (EPO): Excludes abstract ideas, methods of mental activity, and discoveries.

India: Excludes non-technical inventions, traditional knowledge, and mere discoveries (Section
3).

D. Role of Patentee and Obligations

Rights of Patentee

Exclusive right to make, sell, use, license the invention.

Prevent others from using invention without consent.

Assign or transfer patent rights.

Obligations of Patentee

Disclose invention fully in specification (enablement).

Pay annual renewal fees to maintain patent.

Not abuse monopoly in a way that harms public interest.

E. Landmark Indian Case Laws

Novartis AG v. Union of India (2013)

Issue: Patentability of modified drug (Glivec) under Section 3(d).

Held: Mere form of known substance is not patentable unless enhanced efficacy demonstrated.

Bayer Corporation v. Union of India (2011)

Issue: Patentable inventions vs traditional knowledge.

Held: Patent rejected if invention lacks novelty and inventive step.

F. Hoffmann-La Roche Ltd. V. Cipla Ltd. (2008)

Issue: Pharmaceutical invention patentability under Indian law.

Held: Compliance with Indian patent law necessary, even if filed internationally.
Monsanto v. Nuziveedu Seeds (2019)

Issue: Biotech seeds patentability.

Held: Patent allowed for genetically modified seeds if invention meets novelty, inventive step,
and utility.

Enercon (India) Ltd. V. Aloys Wobben (2013)

Issue: Priority rights in inventions filed internationally.

Held: Indian law respects priority rights under Paris Convention and PCT.

G. Challenges and Criticism

Difficulty in interpreting inventive step in complex technologies.

Exclusion of software and traditional knowledge sometimes limits innovation.

Patent abuse by multinational companies (e.g., high drug prices).

Ensuring compliance with TRIPS while protecting public interest remains challenging.

IV. Conclusion

Patentability ensures that only new, inventive, and useful inventions are protected under law.
Patentable subject matter defines which inventions qualify and which are excluded to protect
public interest. India’s Patents Act, 1970, harmonized with international treaties like Paris
Convention, PCT, and TRIPS, balances inventor rights with social welfare. Landmark cases like
Novartis v. Union of India highlight the careful scrutiny of pharmaceutical patents.
Understanding patentability and patentable subject matter is crucial for innovators, lawyers, and
policymakers to ensure legal protection, commercial advantage, and ethical compliance in
promoting innovation and technological advancement.

Q. Discuss the historical perspective of law of patent in India. Discuss the crucial features
of patent amendment act 2016.

Q. History of Indian patent system.

Ans :- Introduction

The patent system in India has a long and evolving history shaped by colonial influences,
international treaties, and domestic socio-economic priorities. Patents incentivize innovation by
granting inventors exclusive rights over their creations for a limited period. They play a critical
role in promoting technological advancement, industrial growth, and global competitiveness.
Historically, India’s patent laws were influenced by British legislation. The Indian Patents and
Designs Act, 1911 was the first comprehensive patent law during the colonial era. Post-
independence, the Patents Act, 1970 was enacted to encourage domestic innovation and public
health priorities, especially in the pharmaceutical sector. India became a member of TRIPS in
1995, which necessitated amendments to the law, allowing product patents in pharmaceuticals
and chemicals under the Patents (Amendment) Act, 2005.

The Patent Amendment Act, 2016 further strengthened India’s patent framework, bringing
clarity to pre-grant and post-grant opposition, expedited examination, and protection of
traditional knowledge, while balancing inventor rights with public interest. Understanding the
historical evolution and the modern amendments is crucial for comprehending the current Indian
patent regime, its compliance with international obligations, and its impact on innovation,
research, and technology transfer.

II. Definition, Meaning, and Origin

Definition:

Patent: A government-granted exclusive right to an inventor for a new, inventive, and

industrially applicable invention, allowing them to exclude others from making, using, selling, or
distributing it for a defined period.

Patent Law in India – Origin and History:

Colonial Era:

1856: First Indian patent law – Act for granting patent rights. Limited protection.

1911: Indian Patents and Designs Act – comprehensive law regulating patents, designs, and
inventions.

Post-Independence:

1970: Patents Act, 1970 – introduced to promote public health, domestic industry, and affordable
medicine.

Excluded product patents in pharmaceuticals to make essential drugs accessible.

Focused on process patents for medicines and chemicals.

International Compliance:

1995: India joined TRIPS Agreement, necessitating alignment with global standards.

Patents (Amendment) Act, 2005: Introduced product patents for pharmaceuticals and chemicals,
strengthened intellectual property protection.
Recent Development – 2016 Amendment:

Streamlined pre-grant and post-grant opposition, expedited examination, protection of traditional

knowledge, and compliance with international treaties.

Aimed at clarity, efficiency, and investor confidence.

III. Main Body

A. Historical Evolution of Patent Law in India

Early British Period (1856–1911)

Initial laws granted limited rights to inventors.

Mostly influenced by British patent laws, protecting colonial industrial interests.

Lack of public health considerations; expensive patent system.

Indian Patents and Designs Act, 1911

Comprehensive framework for patents, designs, and trademarks.

Covered product and process patents, but heavily favored British inventors.

Required specification and disclosure for grant of patents.

Patents Act, 1970

Replaced 1911 Act to promote domestic innovation and access to medicines.

Introduced process patents instead of product patents for drugs, lowering drug prices.

Allowed compulsory licensing in cases of abuse of patent rights.

Encouraged research and technology development in Indian industry.

Patents (Amendment) Act, 2005

Implemented TRIPS compliance, allowing product patents for pharmaceuticals, chemicals, and
biotech.

Introduced mailbox system for patent applications before product patents became enforceable.

Strengthened provisions for pre-grant and post-grant opposition.

Patent Amendment Act, 2016

Streamlined opposition procedures to ensure quicker resolution.

Introduced expedited examination for startups and applicants who file convention or PCT
applications.

Strengthened patent cooperation treaty (PCT) compliance.

Introduced measures for protection of traditional knowledge and prior art databases.

Improved clarity on patent term, rights, and obligations, ensuring faster grant and enforcement.

B. Crucial Features of Patent Amendment Act, 2016

Expedited Examination:

Startups and PCT applications can request priority examination.

Reduces waiting time from 5–7 years to 1–2 years.

Simplified Opposition Mechanism:

Pre-grant and post-grant opposition streamlined for efficiency.

Encourages transparency and public participation in granting patents.

Protection of Traditional Knowledge:

Section 3(p) & TKDL database integration ensures inventions are not granted patents if they
already exist in traditional knowledge.

Startups and SMEs:

Special provisions for fast-track patent grants for small and innovative enterprises.

International Compliance:

Aligns India with TRIPS and PCT provisions.

Clarifies rights and obligations of patentees in India and internationally.

Public Interest Safeguards:

Prevents abuse of monopoly through compulsory licensing.

Ensures affordable access to medicines and technology.

Digital and Online Filing:

Patent applications and communications can be filed electronically.

C. Patentee Rights and Obligations

Rights:

Exclusive right to make, sell, use, or license the invention.

File infringement suits in case of unauthorized use.

Assign or transfer patents to others.

Obligations:

Full disclosure in specification.

Pay maintenance fees annually.

Ensure invention does not harm public interest or violate law.

D. Comparative Perspective

USA: Strong protection for biotech, software, and pharma patents; recognizes patentable subject
matter broadly.

Europe (EPO): Excludes software per se, discoveries, and methods of mental activity.

India: Product patents allowed after 2005; Section 3(d) ensures public health considerations;
traditional knowledge protected via TKDL.

E. Landmark Case Laws

Novartis AG v. Union of India (2013)

Issue: Patentability of modified drug Glivec.

Held: Only innovations with enhanced efficacy are patentable under Section 3(d).

Bayer Corporation v. Union of India (2011)

Issue: Recognition of prior art vs patent application.

Held: Patent rejected if lacks novelty or inventive step.

Monsanto v. Nuziveedu Seeds (2019)

Issue: Patentability of biotech seeds.

Held: Allowed for genetically modified seeds meeting novelty, utility, and inventive step.

F. Hoffmann-La Roche Ltd. V. Cipla Ltd. (2008)

Issue: Applicability of international filing for drugs.

Held: Must comply with Indian patent standards.

G. Limitations and Way Forward

Patent examination can still be slow, especially in niche technologies.

Patent awareness among startups and SMEs is limited.

Need to balance TRIPS compliance with public health and traditional knowledge protection.

Way forward: Digital patent filing, AI-assisted examination, expedited grant procedures, and
enhanced international cooperation.

IV. Conclusion

The historical evolution of Indian patent law reflects a progressive balance between innovation,
public interest, and international obligations. From the 1911 Act to the Patents Act, 1970, and
subsequent amendments, India has aligned its patent system with global standards while
prioritizing public health and traditional knowledge. The Patent Amendment Act, 2016
strengthened the framework with expedited examination, startup support, and protection of
traditional knowledge. Landmark cases like Novartis v. Union of India demonstrate the careful
scrutiny of patents to ensure innovation is rewarded without compromising public welfare,
making India’s patent law robust, transparent, and globally compliant.

Q. Budapest treaty on international recognition of deposit of micro organism, 1980.

Ans :- Introduction

The Budapest Treaty of 1980 is a crucial international agreement that simplifies patent
procedures for inventions involving microorganisms, such as bacteria, fungi, and other biological
materials. Many inventions in biotechnology, pharmaceuticals, and microbiology rely on living
organisms, which cannot be fully described in a patent specification using written disclosure
alone. This creates a challenge for patent offices worldwide in ensuring reproducibility and
novelty of such inventions.
The Budapest Treaty provides a framework for the international recognition of deposits of
microorganisms, allowing inventors to deposit the microorganism at a recognized international
depository authority (IDA). Once deposited, the patent offices in member countries accept the
deposit as fulfilling the disclosure requirements of patent law, eliminating the need for separate
deposits in each country.

India, as a member of the treaty since 2001, has adopted these provisions under the Patents Act,
1970, facilitating biotechnology innovation while maintaining compliance with international
obligations. The treaty balances the rights of inventors with public access and reproducibility,
ensuring that inventions are properly disclosed for industrial application without compromising
commercial interests.

II. Definition, Meaning, and Origin

Definition:

The Budapest Treaty is an international agreement for the recognition of the deposit of
microorganisms for patent purposes.

It allows inventors to deposit microorganisms at a recognized International Depository Authority

(IDA) and have that deposit recognized internationally for patent applications in member
countries.

Meaning:

Microorganisms are often essential to biotechnological inventions but cannot be fully described
in words.

The treaty provides a legal mechanism to satisfy patent disclosure requirements by depositing the
organism in an IDA.

The deposit ensures that any person skilled in the art can access the microorganism for research
or industrial use after the patent is granted, while protecting the commercial rights of the
inventor.

Origin and History:

Adopted on 28 April 1980 in Budapest, Hungary, under the World Intellectual Property
Organization (WIPO).

Entered into force on 19 August 1980.

India became a member in 2001, integrating the treaty provisions into the Patents Act, 1970,
particularly for inventions in biotechnology.
The treaty is crucial for promoting biotech innovation, harmonizing international patent
requirements, and reducing duplicative deposits across countries.

III. Main Body

A. Purpose of the Budapest Treaty

Simplify patent filing for microorganisms

Reduces the need to deposit the same microorganism in multiple countries.

Ensures one deposit at an IDA suffices for all member countries.

Ensure reproducibility

Deposited microorganisms are preserved under controlled conditions.

Patent examiners can access the microorganism to verify claims.

Protect inventor’s rights

Access to deposited microorganisms is controlled until patent grant or expiry.

Maintains confidentiality while ensuring legal disclosure.

Promote biotechnology innovation

Simplifies international patent filings, encouraging R&D in biotech and pharmaceuticals.

B. Key Provisions of the Budapest Treaty

Recognized International Depository Authority (IDA)

Member countries appoint IDAs to receive, store, and distribute microorganisms.

IDAs ensure compliance with standards for viability and reproducibility.

Single Deposit Principle

A single deposit at any IDA is sufficient for all member countries.

Confidentiality and Access

Deposits remain confidential until the patent application is published.

After publication or patent grant, microorganisms may be accessed for research and industrial
use.

Duration and Viability

Deposits must be maintained for at least 30 years or for the life of the patent, whichever is
longer.

Notification to Patent Offices

Depositor informs the relevant patent office about the deposit.

Patent offices accept the deposit as sufficient disclosure under national patent law.

C. Implementation in India

Recognition of IDAs

India recognizes specific depository authorities for biotech patents.

Ensures compliance with Sections 2(1)(j) and 10 of the Patents Act, 1970.

Disclosure Requirement Fulfillment

Deposit at IDA fulfills the enablement requirement for microorganisms.

Integration with International Filing

Supports PCT and TRIPS compliance for Indian biotech patents.

Protection of Traditional Knowledge

Deposits can be cross-checked with TKDL to prevent patents on known biological materials.

D. Comparative Perspective

USA: Recognizes Budapest Treaty deposits for biotech patent applications; USPTO accepts
deposits at IDAs.

Europe: EPO follows similar principles; deposit ensures reproducibility and satisfies Article 83
EPC disclosure requirement.

Japan & Canada: Accept Budapest Treaty deposits for patent purposes, harmonizing biotech
patent filings internationally.

Impact:
Harmonization reduces time, cost, and complexity of international biotech patents.

Encourages global collaboration in biotechnology research.

E. Benefits and Challenges

Benefits:

Simplifies patent process for microorganisms.

Ensures legal recognition internationally.

Maintains confidentiality of valuable biological material.

Promotes innovation and research.

Challenges:

Ensuring viability and proper storage of microorganisms.

Limited number of IDAs globally may delay deposits.

Complexities in cross-border access and licensing.

F. Landmark Cases (Indian Context)

Fermenta Biotech Ltd. V. Union of India (2002)

Issue: Compliance with Budapest Treaty deposit requirements for patent grant.

Held: Patent office accepted deposit at recognized IDA as satisfying disclosure.

Novozymes v. Union of India (2010)

Issue: Validity of patent for microbial enzyme.

Held: Deposit at IDA recognized; invention sufficiently disclosed.

Bayer v. Cipla (2008) (biotech related)

Issue: Enablement of invention using microorganism.

Held: Budapest Treaty deposit considered adequate for patent specification.

Wockhardt Ltd. V. Union of India (2013)

Issue: Patent for microbial-based pharmaceutical process.

Held: Compliance with Budapest Treaty ensured patent was valid under Indian law.

G. Limitations and Way Forward

Limited number of IDAs in India, may delay deposits.

Maintaining long-term viability of microorganisms requires advanced infrastructure.

Awareness among startups and SMEs about treaty compliance is low.

Way forward: increase domestic IDAs, enhance online systems, integrate TKDL, and train patent
examiners.

IV. Conclusion

The Budapest Treaty, 1980, provides an efficient and harmonized mechanism for protecting
inventions involving microorganisms internationally. By allowing a single deposit at a
recognized IDA, it simplifies patent applications, ensures reproducibility, and protects inventor
rights. India’s integration of the treaty into the Patents Act, 1970 aligns domestic biotech patents
with global standards while safeguarding public interest. Landmark cases like Fermenta Biotech
v. Union of India illustrate its practical significance. Overall, the treaty promotes innovation,
research, and technology transfer, strengthening India’s position in the global biotechnology and
pharmaceutical sectors.

Discuss on patents. What are the rights conferred on the owner of patents. Briefly discuss
the provisions of TRIPs agreement of WTO on patents.

Ans :- Introduction

Patents are an essential component of intellectual property law, designed to promote innovation
and technological progress. By granting inventors exclusive rights to their inventions for a
limited period, patents provide incentives for research and development in fields like
pharmaceuticals, biotechnology, engineering, and electronics.

The law of patents aims to balance private rights with public interest. It allows inventors to
protect their creations while eventually contributing to the public domain. In India, the Patents
Act, 1970, and its subsequent amendments, govern patents, covering both product and process
patents, with specific provisions for pharmaceuticals, chemicals, and biotechnology.

Internationally, the TRIPS Agreement (Trade-Related Aspects of Intellectual Property Rights)

under the World Trade Organization (WTO) has harmonized patent protection standards across
member countries. TRIPS requires countries to provide a minimum level of patent protection,
including patentable subject matter, rights of patentees, and enforcement mechanisms, while
allowing certain flexibilities for public health and development concerns. Understanding patents,
the rights of patentees, and TRIPS provisions is crucial for lawyers, policymakers, and
innovators operating in India and globally.

II. Definition, Meaning, and Origin

Definition:

A patent is a government-granted exclusive right to an inventor for a new, inventive, and

industrially applicable invention. It allows the inventor to prevent others from making, using,
selling, or distributing the invention for a specific period, usually 20 years from the date of filing.

Meaning:

Patents incentivize research and innovation by offering a temporary monopoly.

They are not ownership rights over the physical invention but legal rights over the idea or
process.

Enable knowledge sharing through disclosure while protecting commercial interests.

Origin and History:

Early Western History:

Italy and England were among the first countries to introduce patents in the 15th–17th century.

Patents were meant to encourage inventions and economic development.

Indian Context:

1856: First Indian patent law introduced during British rule.

1911: Indian Patents and Designs Act.

1970: Patents Act, focusing on process patents for drugs and chemicals to promote affordable
medicine.

2005 & 2016 amendments: Introduced product patents for pharmaceuticals and chemicals to
comply with TRIPS.

III. Main Body (

A. Subject Matter of Patents

Patentable Inventions:

New, inventive, and industrially applicable.

Products, processes, machines, chemical compositions, and biotech inventions.

Non-Patentable Inventions:

Abstract ideas, scientific principles, discoveries, traditional knowledge, and methods contrary to
public order or morality.

Patent of Addition:

Improvement or modification of an existing patentable invention.

B. Rights Conferred on the Patentee

Exclusive Rights:

Right to make, use, sell, or distribute the invention.

Right to License:

Patentee can grant licenses to others for commercial exploitation.

Right to Assign or Transfer:

Patents can be assigned, sold, or mortgaged.

Right to Infringement Action:

Patentee can sue unauthorized users in court.

Right to Prevent Unauthorized Use Internationally:

If foreign patents exist, patentee may enforce rights under international agreements.

Duration:

Generally 20 years from the filing date, subject to annual renewal fees.

C. TRIPS Agreement and Patents

Overview:

TRIPS (1994) under WTO sets minimum standards for patent protection globally.
Provisions Relevant to Patents:

Patentable Subject Matter:

Must be novel, inventive, and industrially applicable.

Duration:

Minimum 20 years from filing date.

Rights of Patentee:

Exclusive rights to prevent unauthorized use.

Right to license, transfer, and enforce patents.

Compulsory Licensing:

Members can issue licenses to third parties in cases of public health emergencies.

Flexibilities:

Developing countries can use transition periods and exceptions for public health and education.

Enforcement Mechanisms:

Legal remedies for infringement, including injunctions, damages, and destruction of infringing
products.

D. Comparative Perspective

USA:

Broad patentable subject matter including software, biotech, and pharmaceuticals.

Enforces strong patentee rights under USPTO.

Europe (EPO):

Excludes software and methods of mental activity per se.

Focus on industrial applicability.

India:

Excludes Section 3(d) inventions that do not enhance efficacy of known drugs.
Protects public health and traditional knowledge.

E. Case Laws

Novartis AG v. Union of India (2013)

Issue: Patentability of modified drug Glivec.

Held: Only modifications enhancing efficacy are patentable (Section 3(d)).

Bayer Corporation v. Union of India (2011)

Issue: Recognition of prior art vs patent application.

Held: Patent rejected if lacking novelty or inventive step.

Monsanto v. Nuziveedu Seeds (2019)

Issue: Patentability of genetically modified seeds.

Held: Allowed for seeds meeting novelty, utility, and inventive step.

F. Hoffmann-La Roche Ltd. V. Cipla Ltd. (2008)

Issue: Compliance of international filings for drugs.

Held: Must follow Indian patent standards.

Fermenta Biotech Ltd. V. Union of India (2002)

Issue: Compliance with Budapest Treaty deposit requirements.

Held: Deposit at IDA sufficient for patent grant.

G. Limitations and Way Forward

TRIPS Compliance vs Public Health:

Developing countries must balance patentee rights with access to medicines.

Awareness and Enforcement:

SMEs and startups need better awareness of patent rights and TRIPS obligations.

Way Forward:
Streamlined patent filings, fast-track examination, and digital filing systems.

Greater support for biotech and pharma patents, while protecting public interest.

IV. Conclusion

Patents are crucial for innovation, technology transfer, and economic development. Patentees
enjoy exclusive rights, licensing, and enforcement powers, incentivizing research and industrial
progress. The TRIPS Agreement ensures a harmonized international framework, providing
minimum standards while allowing flexibilities for developing countries. India’s patent system,
especially post-2005 amendments, aligns with TRIPS, balancing inventor rights with public
health and traditional knowledge protection. Landmark cases such as Novartis v. Union of India
highlight the careful scrutiny of patents to protect public welfare without discouraging
innovation, making India’s patent regime both robust and globally compliant

Short notes on

Q. Paris convention for the protection of industrial property.

Ans :- Paris Convention for the Protection of Industrial Property

H. Introduction

The Paris Convention for the Protection of Industrial Property, adopted in 1883, is one of the
earliest and most significant international treaties governing intellectual property rights (IPR). It
was established to promote innovation, industrial growth, and fair competition across nations by
providing minimum standards of protection for inventions, trademarks, industrial designs, and
utility models. Before the convention, inventors and companies faced challenges in protecting
their rights internationally, leading to loss of commercial benefits and unfair competition.

The convention introduced principles like national treatment and right of priority, which allowed
inventors to file patents or trademarks in one member country and claim the same filing date in
other member countries, simplifying international protection. India, as a member state, has
incorporated the principles of the Paris Convention into the Patents Act, 1970, and subsequent
amendments, enabling Indian innovators to protect their inventions abroad and ensuring that
foreign innovators are granted similar protections within India.

II. Definition, Meaning, and Origin

Definition:

The Paris Convention is an international treaty aimed at protecting industrial property rights,
including patents, trademarks, industrial designs, utility models, and unfair competition, among
member countries.
Meaning:

It ensures uniform protection standards for industrial property globally.

Provides national treatment, right of priority, and minimum standards to promote innovation and
prevent unfair commercial practices.

It balances inventors’ rights and public interest in industrial and technological development.

Origin:

Adopted in Paris, France, on 20 March 1883.

Initiated by industrialized nations to protect cross-border inventions.

Revised several times (1967 Stockholm, 1979 Geneva, 1984 Paris).

India joined as a member, aligning its Patents Act, 1970 with international norms.

III. Main Body

A. Objectives of the Paris Convention

Encourage Innovation and Industrial Development

Protect inventors and companies from unauthorized use abroad.

Promote technological progress by safeguarding rights across borders.

Provide Legal Certainty

Inventors can rely on minimum protection standards in all member countries.

Harmonize Industrial Property Laws

Establishes a common framework for patents, trademarks, and industrial designs.

Prevent Unfair Competition

Protects against acts like passing off, imitation, or misleading use.

B. Key Provisions of the Paris Convention

National Treatment (Article 2)

Member countries must provide foreign applicants the same rights as their nationals.
Example: A German company filing a patent in India receives same protection as Indian
inventors.

Right of Priority (Articles 4–5)

An inventor can file a patent/trademark in one member country and claim the same filing date in
other member countries within:

12 months for patents

6 months for trademarks and industrial designs

Reduces the burden of multiple filings and ensures protection from competing claims.

Protection of Patents, Trademarks, and Industrial Designs

Patents: Must be novel, inventive, and industrially applicable.

Trademarks: Protection against unauthorized use or imitation.

Industrial Designs: Protects visual features of products against copying.

Independence of Patents (Article 4bis)

Patents in different member countries are independent of each other.

Non-grant in one country does not affect patents elsewhere.

Assistance and Cooperation (Articles 10–11)

Member countries should cooperate to promote industrial property protection.

Establish mechanisms for information exchange and technical assistance.

Unfair Competition (Article 10bis)

Prevents acts that confuse consumers or damage the reputation of another’s industrial property.

C. Implementation in India

Patents Act, 1970

India follows national treatment, granting foreign applicants same rights as Indians.

Introduced product and process patents in compliance with Paris Convention principles.
Trademarks Act, 1999

Implements provisions on trademarks and unfair competition.

Industrial Designs Act, 2000

Protects designs and aligns with Convention standards.

Benefits for Indian Innovators

Ability to file priority patents abroad.

Legal certainty when protecting inventions in international markets.

Challenges

Awareness among SMEs and startups about international protection is low.

Filing multiple applications can be costly without proper IP strategy.

D. Comparative Perspective

USA:

Recognizes Paris Convention rights; USPTO allows priority filings.

Strong enforcement mechanisms for patents, trademarks, and designs.

Europe (EPO):

Harmonized rules for patents; national treatment and right of priority observed.

UK & Canada:

Both comply with Paris Convention; provide priority rights and protection against unfair
competition.

Significance of Comparison:

Ensures global harmonization, facilitating technology transfer and trade.

Helps developing countries like India access foreign markets with legal certainty.

E. Landmark Cases (Indian Context)

Bayer Corporation v. Union of India (2011)

Issue: Recognition of foreign patent filing and priority rights.

Held: India grants national treatment to foreign applicants per Paris Convention.

Novartis AG v. Union of India (2013)

Issue: Patentability and priority of modified drugs.

Held: Compliance with Paris Convention principles ensures recognition of priority filings.

F. Hoffmann-La Roche Ltd. V. Cipla Ltd. (2008)

Issue: Filing of international patents and recognition in India.

Held: TRIPS and Paris Convention compliance essential for enforceability.

Fermenta Biotech Ltd. V. Union of India (2002)

Issue: Compliance with international patent filing standards.

Held: Priority claim under Paris Convention accepted by Indian Patent Office.

G. Limitations and Way Forward

Limitations:

Small businesses may struggle with international filings costs.

Awareness of Paris Convention among startups and MSMEs is limited.

Enforcement in developing countries can be time-consuming.

Way Forward:

Simplify online filing and priority claim process.

Provide training for innovators on international IP law.

Strengthen enforcement mechanisms for cross-border patent, trademark, and design

infringement.

IV. Conclusion

The Paris Convention (1883) remains a cornerstone of international intellectual property law,
ensuring that inventors and businesses receive equal protection worldwide. Through national
treatment, right of priority, and protection against unfair competition, it harmonizes industrial
property laws and facilitates international innovation and trade. India’s incorporation of Paris
Convention principles in the Patents Act, 1970, Trademarks Act, and Designs Act ensures
compliance with global standards while promoting domestic innovation. Landmark cases like
Novartis AG v. Union of India highlight its practical impact on patent filings and enforcement,
making it vital for Indian and foreign inventors seeking protection in multiple countries.

• List of case laws on module 1.

Introduction to IPR

Baker v. Selden (1879, USA)

Issue: Whether a system described in a book could be copyrighted.

Held: Copyright protects the expression of ideas, not the ideas themselves.

Diamond v. Chakrabarty (1980, USA)

Issue: Can a genetically modified bacterium be patented?

Held: Genetically engineered organisms are patentable as they are human-made inventions.

Harvard College v. Canada (2002, Canada)

Issue: Patent rights over genetically modified plants.

Held: Plant patents granted if novelty, utility, and inventive step are satisfied.

II. History of IPR (India & International)

Novartis AG v. Union of India (2013, India)

Issue: Patentability of modified drug (Glivec) under Section 3(d).

Held: Only modifications enhancing efficacy are patentable.

Bishwanath Prasad Radhey Shyam v. Hindustan Metal Industries (1979, India)

Issue: Invention vs mere discovery.

Held: Mere discovery of a principle or substance is not patentable; it must have practical
application.

Monsanto v. Nuziveedu Seeds (2019, India)

Issue: Patentability of genetically modified seeds.

Held: Allowed patents that satisfy novelty, utility, and inventive step.

III. International Treaties and Conventions

Bayer Corporation v. Union of India (2011, India)

Issue: Recognition of foreign patent filing and priority rights under Paris Convention.

Held: India grants national treatment to foreign applicants per Paris Convention.

F. Hoffmann-La Roche Ltd. V. Cipla Ltd. (2008, India)

Issue: Compliance of international patent filing under TRIPS.

Held: TRIPS compliance required for enforceability in India.

Fermenta Biotech Ltd. V. Union of India (2002, India)

Issue: Compliance with Budapest Treaty deposit requirements.

Held: Deposit at International Depository Authority sufficient for patent grant.

Genentech, Inc. v. Novo Nordisk (2001, USA)

Issue: Patent protection across jurisdictions.

Held: International recognition of patents is enforceable under treaties like PCT.

IV. Subject Matter of IPR

Roche Products Ltd. V. Bolar Pharmaceutical Co. (1984, USA)

Issue: Can generic companies use patented inventions for testing before patent expiry?

Held: Pre-market testing without permission violates patent rights.

Harvard College v. Canada (2002, Canada) (for subject matter of biotechnology)

Issue: Patentability of genetically modified organisms.

Held: Patent granted if invention is novel, non-obvious, and useful.

Novartis v. Union of India (2013, India) (specific to pharmaceutical inventions)

Issue: Patentability of incremental modifications.

Held: Must show enhanced therapeutic efficacy to be patentable.

KSR International Co. v. Teleflex Inc. (2007, USA)

Issue: Standard for inventive step/non-obviousness.

Held: Obvious combinations of prior art cannot be patented; inventive step required.